Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

For people living with #celiacdisease (CeD), like Bill, accidental gluten exposure can lead to ongoing symptoms and intestinal damage. However, current monitoring often relies on invasive procedures, underscoring the need for minimally invasive biomarkers to assess disease activity. Learn about our dedication to addressing CeD unmet needs: https://lnkd.in/e_GebYBU

We are using AI in more and more ways across our value chain; from processing clinical trial data to optimizing manufacturing. See how we’re applying data, technology and human insight to accelerate impact in our 2025 Annual Integrated Report. https://lnkd.in/eazWB2nA

We are raising awareness about dengue prevention! From New Orleans to Romania, we showed our commitment to global #publichealth and dengue prevention at the #CISTM19 and #ESPID2025 conferences this spring. We had the opportunity to meet with many experts and discuss the dynamics of dengue and the threat it poses to people traveling to or living in endemic regions. We recognize the urgency around dengue fever prevention and are doing our part to elevate dengue discussions around the world! #DengueDoesntDiscriminate #DengueAwareness

We’re breaking down common myths about #psoriasis (PsO), an inflammatory disease affecting the daily lives of approximately 64 million people worldwide. Learn about our commitment to raising awareness, challenging stigmas and supporting the PsO community: https://lnkd.in/eZWXYZAV

In the U.S., 1 in 10 people lack access to health care due to social factors including where they live or work. In FY2024, our programs for community health reached 10.8 million people. Explore how we partner with local organizations and leaders to design solutions in our 2025 AIR. https://lnkd.in/esubqq9w

We are pleased to share results from our FirstLight and RadiantLight global Phase 3 studies for an investigational treatment for people with #narcolepsy type 1 (NT1). NT1 is a rare, chronic neurological disorder that is caused by low levels of orexin neurons in the brain, leading to a disrupted sleep-wake cycle among other symptoms. Read more here: https://lnkd.in/eizbwEM7 For Media and Investors only.

Can you figure out where this Takeda office is? Here’s a big hint: it’s a global hub for our Research and Development, Global Oncology and Global Vaccines business teams. If you said Cambridge, you’re spot on! Want to learn more about our other locations? Check them out here: https://bit.ly/46GvqV5 #MakeHistoryChangeFutures #TeamTakeda

Join our Talent Community and count on being in the know about: • Our history and where we’re headed, including our award wins and latest Takeda news • How our employees are driving technology breakthroughs in healthcare • The role values play throughout every aspect of our business • Career opportunities We're excited to share our journey with you: https://bit.ly/3GCUcL6 #MakeHistoryChangeFutures #TeamTakeda

If you’ve ever wondered what controls the balance of sleep and wakefulness, an important discovery by award-winning scientists points to orexin – a chemical messenger in the brain. It is this messenger that promotes wakefulness and when its levels in the brain are deficient, this causes a rare neurological disorder known as narcolepsy type 1, or NT1. People with NT1 experience excessive daytime sleepiness among other severe daytime and nighttime symptoms, some of which can impact cognition. Learn more about the science of orexin, the origins of its discovery and the research that Takeda is supporting to better understand NT1.https://takeda.info/3IgqwUI This content is intended for general informational purposes only and does not constitute medical advice. Please consult a healthcare professional for guidance.